Pipeline

Place: Japan

Development No.
Generic name
Therapeutic Category Dosage form Stage
F-1515
Lutetium (177Lu) oxodotreotide
Therapy of neuroendocrine tumor (Radiopharmaceuticals) Injection Approved
F-1614
3-Iodobenzylguanidine (131I)
Therapy of pheochromocytoma (Radiopharmaceuticals) Injection Approved
T-4288 Fluoroketolide antibiotic
(Otorhinolaryngology infectious disease)
Oral NDA filing
T-705 Anti-COVID-19 drug Oral NDA filing
T-4288 Fluoroketolide antibiotic
(Respiratory infectious disease)
Oral Phase 3
Favipiravir Anti-SFTS (serious fever with thrombocytopenia syndrome) virus agent Oral Phase 3
F-1311 Diagnosis of prostate cancer (Radiopharmaceuticals) Injection Phase 2
T-817MA Treatment for Alzheimer's disease Oral Phase 2
T-817MA Functional recovery after stroke (Promoting the effect of rehabilitation) Oral Phase 2
FF-21101 Therapy of advanced / recurrent solid cancer (Armed antibody) Injection Phase 1

(As of Sep. 2021)

Place: Overseas

Development No.
Generic name.
Therapeutic Category Dosage form Stage
T-705 Anti-COVID-19 drug Oral Phase 2 (U.S.)
T-817MA Treatment for Alzheimer's disease Oral Phase 2 (U.S.)
Phase 2 (Europe)

* FUJIFUILM group will conduct development in the foreign country.

(As of Sep. 2021)

FUJIFILM Toyama Chemical Co., Ltd. has following patent rights of the compounds of development number described above.
In these countries, acts of making, selling or offering to sell these compounds infringe the following patent rights of FUJIFILM Toyama Chemical Co., Ltd. without the permission of FUJIFILM Toyama Chemical Co., Ltd.
Please make sure not to infringe patent rights of FUJIFILM Toyama Chemical Co., Ltd.

T-705

Japanese patent No. 3453362

T-3811

Japanese patents Nos. 3031722 and 3281872

T-817MA

US patent No. RE43676, EP patent No. 1437353, Chinese patent No. ZL02820645.2, Japanese patent No. 4398247

Other countries(To an external site)

T-2307

US patent No. 7291617, EP patent No. 1481966, Chinese patent No. ZL03807452.4, Japanese patent No. 4320260

Other countries(To an external site)